



MERGER ANNOUNCEMENT - M/19/017

Competition and Consumer Protection Commission clears proposed acquisition by Duke Street LLP of sole control of DCC Vital (UK) Limited and Kent Pharma UK Limited.

02 August 2019

On 02 August 2019, the Competition and Consumer Protection Commission cleared the proposed transaction, whereby Duke Street LLP, via DS Spring Bidco Limited which it ultimately controls, would acquire sole control of DCC Vital (UK) Limited and Kent Pharma UK Limited. The proposed transaction was notified under the Competition Act 2002, as amended, on 25 June 2019.

The Commission has formed the view that the proposed transaction will not substantially lessen competition in any market for goods or services in the State. The Commission will publish the reasons for its determination on its website no later than 60 working days after the date of the determination and after allowing the parties the opportunity to request that confidential information be removed from the published version.

Additional Information

The acquirer, DS Spring Bidco Limited, is a portfolio company ultimately controlled by Duke Street LLP. Duke Street LLP is a private equity firm specialising in investing in mature, mid-market western European businesses. Duke Street LLP focuses on four primary sector markets, Consumer, Healthcare, Industrials and Engineering, and Services.

Kent Pharma UK Limited is involved in the manufacture, supply and service of generic medicines across hospitals and primary and secondary care sectors. It is currently owned and controlled by Fannin (UK) Limited, and is ultimately owned and controlled by DCC plc.

DCC Vital (UK) Limited sells and distributes a broad range of own and third party pharmaceutical products to healthcare providers across the UK and Ireland. DCC Vital (UK) Limited is owned and controlled by DCC Vital Ireland Limited. All of these entities are ultimately owned and controlled by DCC plc.